5372912026-04-012026-06-305372912026-04-012026-06-30in-capmkt:OtherExpenses1Member5372912026-04-012026-06-30in-capmkt:OtherExpenses2Memberiso4217:INRiso4217:INRxbrli:shares537291NATHBIOGENNOTLISTEDINE448G01010NATH BIO-GENES (INDIA) LIMITEDMain BoardEquity2026-04-012027-03-312026-07-292026-07-18INRLakhsQuarterlyFirst quarterSingle segmentSeeds cultivation2026-07-2913:00:002026-07-2916:00:00Not applicablefalsefalseNot applicable during the current period2026-04-012026-06-30UnauditedStandalone322842800019005000324743300011001140001229000048752100010360300037925000100500001174151000292565400032177900011998000333777000720900007209000032656800000003265680002250003267930001900400001017.1817.180017.1817.18Notes <br /> <br /> 1. The financial results were reviewed by the Audit Committee on 28 July 2026 and were thereafter approved by the Board of Directors at its meeting held on 29 July 2026. <br /> <br /> 2. The short provision of Schemes of Rs. 900.00 Lakhs pertaining to the quarter ending June 2025, as reported in the quarterly results of March 26 is now considered and represented in the results of June 2025. <br /> <br /> 3. The company deals with only one major product segment of Seed Cultivation. Thus, segmental reporting is not provided. <br /> <br /> 4. Investor Complaints: <br /> <br /> a. Received during the quarter - NIL <br /> <br /> b. Pending at the end of quarter - NIL <br /> <br /> 5. The figures have been regrouped/rearranged, wherever necessary.selling and Distribution Expenses1079745000Other Expenses94406000-2250000225000